Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thrombospondin type-1 domain-containing protein 4 (THSD4) is a secreted, non-enzymatic glycoprotein of the ADAMTS-like (ADAMTSL) family that functions as a key extracellular matrix (ECM) structural constituent. THSD4 physically interacts with fibrillin-1, facilitating microfibril assembly crucial for tissue elasticity and integrity in organs such as the aorta, skin, and bone. It plays roles in pulmonary physiology, bone mass regulation, and is implicated as a modulator in the tumor microenvironment of colorectal cancer, restraining TGF-β signaling and cancer metastasis. In the skin, THSD4 supports hair growth by mediating interactions between the dermal papilla and hair matrix, playing a central role in age-related ECM remodeling. Mutations in THSD4 are associated with familial thoracic aortic aneurysm, aortic dissection, and may influence susceptibility to osteoporosis and cancer progression[1][2][3][4][5].
Not targeted by approved drugs; mechanisms relate to promoting microfibril assembly through interaction with fibrillin-1 and attenuation of TGF-β signaling, potentially via sequestration of active/latent TGF-β complexes[4][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thrombospondin type-1 domain-containing protein 4 (THSD4).